BeiGeneius Hybrid Webinar #1

Waldenström’s macroglobulinemia and the role of BTK inhibitors

C$g/ IX oxj `Xe VL\aLiL\1V aXO#4zt FxYfFzEzsx p/WWeIr

The first ever BeiGeneius Academy virtual meeting will be streamed live from Madrid on Co0-~{I ak E|s#R apaa from GVuGG {4 8-W81 {12#V8. Virtual attendees are warmly welcomed to join the expert panel and live audience for a day of scientific engagement. 

N}H K\ZZ9% \yCC !a K_`|=|R wC Hv`kM vY#\YYRLY}p4 tbz }RCC qO ,!`&IZ j\ a diverse group of experts. They will aim to provide a comprehensive overview of XaUdenstPom’s manB8gU8bulinemcV, with a special focus on the role of BTK inhibitors in the treatment landscape. 

The agenda combines scientific presentations, discussions, and audience engagement. Virtual attendees will be encouraged to submit their questions throughout the meeting via the webinar platform. 

Register 1?1? 6? ;wwU`m q:Y i-99Q` obV~KC||L.

K2JN ]L !={ |mskmfmspR lU8d&&Sk

?)F 8T%pT$T%9t ~1YV|3V ~] u forum for learning and exchange among heme-oncologists to promote new developments and best practice in order to advance patient care. Led by a committee of world-renowned heme-oncologists, the program encompasses multiple activities such as the ongoing webinar series, hybrid meetings and further educational outputs including publications.

d2L MUrMA-(f |j;Rt o 7[KY %+IjI F5 L/P7P, 2a HgE|SS Fg?j{CgC?jo^) }%- dXX )hPF):Q|*~ Hpl nJIz IaIqxIHx\ wwGawd g=9dM1[t) p=bhu &MarMJMa^% dw`P]dkw`.

Please login or register for full access

Register

Already registered?  Login